Once again, I find myself in the pharmaceutical industry (surprise!). This time, however, I am with Eli Lilly and Company...in the Regulatory Affairs Department, no less.
If you remember from my previous adventures, I spent a summer in regulatory affairs at Abbott in Advertising and Promotion. You're probably thinking, what's the point of doing two regulatory affairs positions? I had the same thought, believe me.
What I didn't know was that I would be working on the complete opposite spectrum of the drug development process. At Abbott, I dealt with the regulations after the FDA approved a drug. At Lilly, I deal with the regulations before and during FDA approval. Yup, I'm working with Investigational New Drug (IND) applications and New Drug Applications (NDA).
I'm currently wrapping up a journal club presentation for this upcoming Tuesday on a competitor's newly approved biologic drug and will finish the rest of the clerkship gathering intelligence on a project that's under Double Secret Probation. I wish I could say more, but these industry folk like to keep to themselves.
No comments:
Post a Comment